# Safety and Efficacy Study of a Recombinant and Protein-Free Factor VIII (rAHF-PFM) in Hemophilia A Patients Undergoing Surgery

> **NCT00157105** · PHASE2,PHASE3 · COMPLETED · sponsor: **Baxalta now part of Shire** · enrollment: 59 (actual)

## Conditions studied

- Hemophilia A

## Interventions

- **DRUG:** Antihemophilic factor, recombinant, manufactured protein-free

## Key facts

- **NCT ID:** NCT00157105
- **Lead sponsor:** Baxalta now part of Shire
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-02-12
- **Primary completion:** 2004-08-03
- **Final completion:** 2004-08-03
- **Target enrollment:** 59 (ACTUAL)
- **Last updated:** 2021-08-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00157105

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00157105, "Safety and Efficacy Study of a Recombinant and Protein-Free Factor VIII (rAHF-PFM) in Hemophilia A Patients Undergoing Surgery". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00157105. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*